By Maurice Bellan and Aleesha Fowler ( January 28, 2019, 5:18 PM EST) -- On Dec. 11, 2018, the United States Attorney's Office for the District of New Jersey submitted a statement of interest to a federal court, asking the court to rule on a specific question of law that implicates the scope of the materiality standard in False Claims Act jurisprudence: Whether a pharmaceutical company that violates the anti-kickback statute, or AKS, and causes a hospital to submit reimbursement claims for non-covered uses of a drug, can be held liable under the FCA if the federal government pays for the drug through a flat, bundled payment....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.